University of Michigan Comprehensive Cancer Center Support Grant

密歇根大学综合癌症中心(UMCCC)要求在#年续签其核心拨款 支持高层领导、计划和共享的核心设施。支持UMCCC的核心赠款 最初是由NCI于1988年授予的，此后一直提供资金。马克斯·维查博士，创始人 癌症中心主任，继续担任主任。该中心提供了一个组织 促进跨学科癌症研究的框架，通过制定明确的临床、基础、 以及癌症研究和共享核心资源开发方面的预防计划。在1997年， 中心搬进了一座耗资8800万美元的新设施，里面有中心的门诊诊所以及许多 它的研究实验室。癌症中心在这方面继续经历着相当大的增长 授权期内招聘了70名新教师，NCI的资金增加了85%。癌症中心的13个 研究项目包括癌症遗传学、癌细胞生物学、 分子治疗学、放射科学和分子成像。临床研究项目包括 前列腺癌/泌尿科、乳腺癌、白血病/淋巴瘤-骨髓移植、骨髓瘤、儿童癌症和头颈 癌症。预防方案包括两个方案：生物医学预防和社会行为预防。 共请求为16个共享核心设施提供支助。其中包括临床试验、生物统计学、 组织采购，肿瘤成像，DNA测序，形态学，流式细胞术，实验 辐射，动物设施，转基因小鼠，载体核心，免疫监测，cDNA Affymetrix和 微阵列和三个新的核心，包括蛋白质组学、生物信息学和健康通信。 还需要资金用于发展、规划和评估，以及支持中心的管理 目标。医疗中心已经向癌症中心做出了实质性的承诺，大约 1.75亿美元。其285个UMCCC成员获得了超过8200万美元的研究资金，其中包括超过3700万美元 每年直接向NCI提供100万美元的支持。UMCCC对癌症研究产生了重大影响，因为 证据是在高影响力的期刊上发表了至少315篇文章，将52%的UMCCC干预 研究人员发起的试验的收益，并一直位居十大癌症中心之列 全国范围内的NCI在这一赠款期间的资金。

The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of Senior Leadership, Programs, and Shared Core Facilities. A core grant to support the UMCCC was initially awarded by the NCI in 1988, with continuous funding since then. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of defined clinical, basic, and prevention programs in cancer research and the development of shared core resources. In 1997 the center moved into a new $88 million facility which houses the center's outpatient clinics as well as many of its research laboratories. The Cancer Center has continued to experience considerable growth over this grant period with 70 new faculty recruited and an 85% increase in NCI funding. The Cancer Center's 13 research programs include the basic research programs in Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences, and Molecular Imaging. Clinical research programs include Prostate/Urological, Breast, Leukemia/Lymphoma-BMT, Gl, Childhood Cancers, and Head & Neck cancers. The prevention programs include two programs: Biomedical Prevention and Socio-Behavioral. Support is requested for a total of 16 shared core facilities. These include Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA Sequencing, Morphology, Flow Cytometry, Experimental Irradiation, Animal Facility, Transgenic Mouse, Vector Core, Immune Monitoring, cDNA Affymetrix and Microarray and three new cores including Proteomics, Bioinformatics, and Health Communications. Funds are also requested for development, planning and evaluation, and administration to support center goals. The Medical Center has made substantial commitments to the Cancer Center of approximately $175 million. Its 285 UMCCC members receive over $82 million in research funding, including over $37 million in annual direct NCI support. The UMCCC has had a major impact on cancer research as evidenced by publishing at least 315 articles in high impact journals, placing 52% of UMCCC intervention accruals onto investigator-initiated trials and consistently ranking among the top ten Cancer Centers nationally for NCI funding over this grant period.